News | Medical Marketing & Media | MM&M

News

Lacquaniti eyes expansion

The selection process was described as extensive and exhaustive, but now that Mary Lacquaniti is settling into her new role as executive director of the Healthcare Marketing and Communications Council (HMC), she is focused on the future.

Pfizer Pfriends program underway

Pfizer announced today that America’s uninsured can now obtain Pfizer prescription medicines at significant savings through more than 52,000 community pharmacies nationwide or via Pfizer’s mail order service. The savings are available through Pfizer’s new program, Pfizer Pfriends.

Giant wins ArgiNox account

ArgiNox Pharmaceuticals, of Menlo Park, Ca named Giant Creative Strategy as the agency of record for their lead compound, tilarginine acetate. Tilarginine acetate is currently being studied in clinical trials for the treatment of cardiogenic shock. Giant will work with ArgiNox to develop an integrated scientific market preparation campaign, as well as naming and all…

HBA adds 10 to its board.

The Healthcare Businesswomen’s Association (HBA) has appointed an additional 10 new members to its 25-member advisory board. Many of the new members are recipients of the HBA’s annual Woman of the Year or Honorable Mentor awards.

Novartis receives supplemental indication for pro-motility agent Zelnorm

Novartis reported that the FDA has approved a supplemental indication for its pro-motility agent Zelnorm for the treatment of chronic idiopathic constipation in male and female patients less than 65 years of age. The new indication is supported by safety and efficacy data from the two largest and longest mrandomized, double-blind, placebo-controlled, multi-national Phase III…

Low-dose version of Prempro approved

The FDA approved a low-dose version of Wyeth Pharmaceuticals‘ hormone replacement therapy Prempro (conjugated estrogens and medroxyprogesterone). The low-dose Prempro has 28 percent less estrogen and 40 percent less progestin than full-dose Prempro, Wyeth reported. It contains 0.45 mg of conjugated estrogens and 1.5 mg of medroxyprogesterone. This version is indicated for use in the…

Light Sciences announce approval for Japanese licensor

Seattle-based Light Sciences reported that Meiji Seika, the licensor of its lead compound, LS11 (Laserphyrin in Japan), received a recommendation for approval by Pharmaceutical Affairs and Food Sanitation Council of the Ministry of Health, Labor and Welfare in Japan. The approval will be granted for the photodynamic treatment of early endobronchial carcinoma. The Japanese regulatory…

Kos Pharmaceuticals and Takeda Pharmaceuticals reach agreement to co-promote Niaspan and Advicor

Kos Pharmaceuticals and Takeda Pharmaceuticals have reached a three-year agreement to co-promote Kos’ Niaspan and Advicor in the U.S. market. The agreement adds more than 1,000 Takeda sales representatives to the existing Kos sales force to detailthe two products developed by Kos for treating cholesterol disorders. Theincreased promotional effort is expected to significantly enhance the…